MCID: VLV010
MIFTS: 44

Vulvovaginitis

Categories: Reproductive diseases

Aliases & Classifications for Vulvovaginitis

MalaCards integrated aliases for Vulvovaginitis:

Name: Vulvovaginitis 12 76 55 44 15 73
Vulvo-Vaginitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2273
ICD10 33 N76.0
MeSH 44 D014848
NCIt 50 C35131
UMLS 73 C0042998

Summaries for Vulvovaginitis

MalaCards based summary : Vulvovaginitis, also known as vulvo-vaginitis, is related to esophagitis and oral lichen planus. An important gene associated with Vulvovaginitis is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are PAK Pathway and Allograft rejection. The drugs Miconazole and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and neutrophil.

Wikipedia : 76 Vaginitis is inflammation of the vagina. In most cases, it is a symptom of an infection of the... more...

Related Diseases for Vulvovaginitis

Diseases related to Vulvovaginitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
# Related Disease Score Top Affiliating Genes
1 esophagitis 29.8 CCL11 CXCL8
2 oral lichen planus 29.8 CCL5 HSPD1
3 chlamydia 29.4 CXCL8 HSPD1 IL10
4 peritonitis 29.3 CXCL8 IL10
5 rhinitis 29.2 CCL11 CCL5 CXCL8
6 human immunodeficiency virus type 1 28.7 CCL11 CCL5 IL10
7 psoriasis 28.6 CCL5 CXCL8 IL10
8 vulvovaginal candidiasis 12.5
9 vulvovaginal gingival syndrome 12.1
10 vulvovaginal rhabdomyosarcoma 12.0
11 vulvovaginitis, allergic seminal 11.9
12 vaginitis 11.4
13 vulvitis 11.2
14 vulvar vestibulitis syndrome 11.2
15 vulvar disease 11.1
16 candidiasis 10.9
17 postmenopausal atrophic vaginitis 10.9
18 mycobacterium fortuitum 10.6 CXCL8 HSPD1
19 papillary conjunctivitis 10.5 CCL11 CXCL8
20 giant papillary conjunctivitis 10.5 CCL11 CXCL8
21 tungiasis 10.5 CXCL8 IL10
22 acute transverse myelitis 10.5 CXCL8 IL10
23 pouchitis 10.5 CXCL8 IL10
24 neurosyphilis 10.5 CXCL8 IL10
25 allergic conjunctivitis 10.5 CCL11 CXCL8
26 necatoriasis 10.5 CXCL8 IL10
27 funisitis 10.5 CXCL8 IL10
28 trichuriasis 10.5 CXCL8 IL10
29 clonorchiasis 10.5 CXCL8 IL10
30 carrion's disease 10.5 CCL11 HSPD1
31 transverse myelitis 10.4 CXCL8 IL10
32 aseptic meningitis 10.4 CXCL8 IL10
33 primary peritoneal carcinoma 10.4 CXCL8 IL10
34 acute pyelonephritis 10.4 CXCL8 IL10
35 trachoma 10.4 HSPD1 IL10
36 prostatitis 10.4 CXCL8 IL10
37 conjunctivitis 10.4 CCL11 CXCL8
38 leptospirosis 10.4 CXCL8 IL10
39 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4 HSPD1 IL10
40 brucellosis 10.4 CXCL8 IL10
41 keratoconjunctivitis 10.4 CCL11 CXCL8
42 pyelonephritis 10.4 CXCL8 IL10
43 peptic ulcer disease 10.4 CXCL8 IL10
44 appendicitis 10.4 CXCL8 IL10
45 dengue hemorrhagic fever 10.3 CXCL8 IL10
46 shigellosis 10.3 CXCL8 IL10
47 mixed connective tissue disease 10.3 HSPD1 IL10
48 periapical granuloma 10.3 CCL5 CXCL8
49 status asthmaticus 10.3 CCL5 CXCL8
50 reactive arthritis 10.3 HSPD1 IL10

Graphical network of the top 20 diseases related to Vulvovaginitis:



Diseases related to Vulvovaginitis

Symptoms & Phenotypes for Vulvovaginitis

Drugs & Therapeutics for Vulvovaginitis

Drugs for Vulvovaginitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
2
Fluconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 86386-73-4 3365
3
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23593-75-1 2812
4
Dequalinium Approved, Investigational Phase 4 6707-58-0
5
Terconazole Approved Phase 4,Not Applicable 67915-31-5 441383
6
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 18323-44-9 29029
7
Ephedrine Approved Phase 4 299-42-3 9294
8
Pseudoephedrine Approved Phase 4 90-82-4 7028
9 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
12 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Anti-Infective Agents, Local Phase 4,Phase 3
18 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Not Applicable
19 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
20 Clindamycin palmitate Phase 4,Phase 3,Not Applicable
21 Clindamycin phosphate Phase 4,Phase 3,Not Applicable
22 Tetrahydrozoline Phase 4,Phase 3
23 Antibiotics, Antitubercular Phase 4,Not Applicable
24 Antitubercular Agents Phase 4
25 Autonomic Agents Phase 4
26 Nasal Decongestants Phase 4
27 Ophthalmic Solutions Phase 4
28 Peripheral Nervous System Agents Phase 4
29 Pharmaceutical Solutions Phase 4,Phase 2
30 Respiratory System Agents Phase 4
31 Vasoconstrictor Agents Phase 4
32
Butoconazole Approved Phase 3,Not Applicable 64872-77-1, 64872-76-0 47472
33
Amphotericin B Approved, Investigational Phase 3,Phase 2 1397-89-3 14956 5280965
34
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576 3823
35
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
36 Antiparasitic Agents Phase 3,Phase 2
37 Antiprotozoal Agents Phase 3,Phase 2
38 Liposomal amphotericin B Phase 3,Phase 2
39
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
40 Adjuvants, Immunologic Phase 1, Phase 2
41 Antacids Phase 1, Phase 2
42 Anti-Ulcer Agents Phase 1, Phase 2
43 Gastrointestinal Agents Phase 1, Phase 2
44 Vaccines Phase 1, Phase 2
45 Acidophilus Nutraceutical Phase 1,Not Applicable,Early Phase 1
46
Iron Approved Not Applicable 7439-89-6 23925
47
Itraconazole Approved, Investigational Not Applicable 84625-61-6 55283
48
Metronidazole Approved ,Not Applicable 443-48-1 4173
49
Hydroxyitraconazole Not Applicable
50 Micronutrients Not Applicable

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
2 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
3 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
4 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
5 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
6 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Recruiting NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
7 Vaginal Infection Study Completed NCT00616330 Phase 3 clindamycin phosphate/butoconazole nitrate;clindamycin phosphate;butoconazole nitrate
8 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
9 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3 Fluconazole
10 Comparative Efficacy of Ovule vs Tablet Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
11 A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
12 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3 Boric;Fluconazole
13 Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Recruiting NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
14 ProF-001_Phase IIa Recruiting NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
15 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Not yet recruiting NCT03562156 Phase 3 VT-1161;Placebo
16 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Not yet recruiting NCT03561701 Phase 3 VT-1161;Placebo
17 Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis Not yet recruiting NCT03473418 Phase 3 Ketoconazole;Terconazole
18 Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis Not yet recruiting NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
19 An Active-Controlled, Dose-Finding Study of SCY-078 vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03253094 Phase 2 Fluconazole;SCY-078
20 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
21 RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Completed NCT02733432 Phase 2 CD101 Vaginal Gel (3%);CD101 External gel (1%);CD101 Vaginal Ointment (6%);CD101 External ointment (1%);Fluconazole
22 TOL-463 Phase 2 Study for Vaginitis Completed NCT02866227 Phase 2 TOL-463;TOL-463
23 Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
24 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Completed NCT02267382 Phase 2 VT-1161;Placebo
25 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
26 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) Completed NCT01891331 Phase 2 VT-1161;Fluconazole
27 MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
28 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
29 Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Not yet recruiting NCT03167957 Phase 2 Oral Encochleated Amphotericin B (CAMB);Oral Encochleated Amphotericin B (CAMB)
30 Patients With Vulvovaginal Candidiasis Not yet recruiting NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
31 Efficacy Vulvovaginitis Candida Terminated NCT00199264 Phase 2 Albaconazole oral solution
32 Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status NCT00479947 Phase 1 Probiotics (Natural product);Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
33 Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Completed NCT02730494 Phase 1
34 Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection Completed NCT01067131 Phase 1
35 Maternal and Perinatal Outcome in Women With History of Premature Labor in Previous Pregnancy Completed NCT01375439 Not Applicable
36 A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations Completed NCT01039584 Not Applicable Butoconazole Nitrate Vaginal Cream;Placebo;Gynazole 1 vaginal cream
37 Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) Completed NCT00895453 Not Applicable itraconazole;lactobacillus gasseri;classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
38 Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis Completed NCT00803738 Not Applicable Terconazole Vaginal Suppository;Terazol Vaginal Suppository
39 Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization Completed NCT02888197
40 Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis Completed NCT02203942
41 Observational Program Neo-Penotran® Forte Completed NCT01335373 Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
42 Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Completed NCT02150655 Early Phase 1
43 Epidemiological Study in Subjects With Vulvovaginal Candidiases Recruiting NCT03064789
44 Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women Recruiting NCT01915251
45 Oral Probiotics for the Treatment and Prevention of Vulvovaginal Infections in Pregnancy - Double-blind, Randomized, Placebo-controlled Study Recruiting NCT02795845 Not Applicable
46 Women's Improvement of Sexual Health (WISH) Demonstration Project Active, not recruiting NCT03045809
47 Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial Not yet recruiting NCT03075046 Not Applicable
48 Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M® Terminated NCT00915629 Not Applicable
49 Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis Terminated NCT02859493 Not Applicable
50 Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis Terminated NCT02345096 Not Applicable

Search NIH Clinical Center for Vulvovaginitis

Cochrane evidence based reviews: vulvovaginitis

Genetic Tests for Vulvovaginitis

Anatomical Context for Vulvovaginitis

MalaCards organs/tissues related to Vulvovaginitis:

41
Testes, Colon, Neutrophil, Skin, Spinal Cord, B Cells, Lymph Node

Publications for Vulvovaginitis

Articles related to Vulvovaginitis:

(show top 50) (show all 819)
# Title Authors Year
1
Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. ( 29975334 )
2018
2
New evidence on oral L. plantarum P17630 product in women with history of recurrent vulvovaginal candidiasis (RVVC): a randomized double-blind placebo-controlled study. ( 29364495 )
2018
3
Risk Factors of Vulvovaginal Candidiasis among Women of Reproductive Age in Xi'an: A Cross-Sectional Study. ( 29977925 )
2018
4
Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. ( 29790255 )
2018
5
A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate theA efficacy and safety of orally administeredA VT-1161 inA the treatment of recurrentA vulvovaginal candidiasis. ( 29534874 )
2018
6
A nested-PCR strategy for molecular diagnosis of mollicutes in uncultured biological samples from cows with vulvovaginitis. ( 29191491 )
2018
7
Pulsatilla decoction inhibits Candida albicans proliferation and adhesion in a mouse model of vulvovaginal candidiasis via the Dectin-1 signaling pathway. ( 29775695 )
2018
8
Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis. ( 29963049 )
2018
9
Surface-modified mucoadhesive microgels as a controlled release system for miconazole nitrate to improve localized treatment of vulvovaginal candidiasis. ( 28986195 )
2018
10
Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: "Neutrophil Anergy". ( 29203543 )
2018
11
Effect of 2-Phenylethanol as Antifungal Agent and Common Antifungals (Amphotericin B, Fluconazole, and Itraconazole) on Candida Species Isolated from Chronic and Recurrent Cases of Candidal Vulvovaginitis. ( 29658789 )
2018
12
Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis. ( 29846682 )
2018
13
Parapoxviral vulvovaginitis in Holstein cows. ( 29429402 )
2018
14
The effect of a vaginal suppository formulation of dill (Anethum graveolens) in comparison to clotrimazole vaginal tablet on the treatment of vulvovaginal candidiasis. ( 29553834 )
2018
15
Nanolipid Gel of an Antimycotic Drug for Treating Vulvovaginal Candidiasis-Development and Evaluation. ( 29340981 )
2018
16
Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. ( 29902998 )
2018
17
Thymol, eugenol and lactobacilli in a medical device for the treatment of bacterial vaginosis and vulvovaginal candidiasis. ( 29874389 )
2018
18
An unusual presentation of pseudocowpox associated with an outbreak of pustular ulcerative vulvovaginitis in a Swedish dairy herd. ( 29153035 )
2018
19
Efficacy, acceptability and tolerability of ZelesseAr for the treatment of non-specific vulvovaginitis in paediatric patients: The NINESSE Study. ( 29877120 )
2018
20
Amphotericin B-Loaded Plga Nanofibers: an Alternative Therapy Scheme for Local Treatment of Vulvovaginal Candidiasis. ( 29940181 )
2018
21
Antimicrobial photodynamic therapy as a new approach for the treatment of vulvovaginal candidiasis: preliminary results. ( 29931589 )
2018
22
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. ( 29932786 )
2018
23
RISK FACTORS OF VULVOVAGINAL CANDIDIASIS IN DERMATO-VENEREOLOGY OUTPATIENTS CLINIC OF SOETOMO GENERAL HOSPITAL, SURABAYA, INDONESIA. ( 29619437 )
2018
24
Longitudinal trajectory of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis during pregnancy as well as the impact on pregnancy outcomes: a preliminary study. ( 29685081 )
2018
25
A Therapeutic Vaccine for Recurrent Vulvovaginal Candidiasis. ( 29697770 )
2018
26
A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. ( 29697768 )
2018
27
Computer-aided diagnosis software for vulvovaginal candidiasis detection from Pap smear images. ( 28987021 )
2018
28
Development, characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis. ( 29361177 )
2018
29
Mannose-Binding Lectin Gene Polymorphism and Its Association with Susceptibility to Recurrent Vulvovaginal Candidiasis. ( 29850562 )
2018
30
Prepubertal vulvovaginitis. ( 29970369 )
2018
31
Formulation, stability study, and pre-clinical evaluation of a vaginal cream containing curcumin in a rat model of vulvovaginal candidiasis. ( 29517833 )
2018
32
Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen? ( 28868834 )
2017
33
Candida Vulvovaginitis and Vulvodynia: The Mystery Continues. ( 28836889 )
2017
34
Recurrent vulvovaginal candidiasis: A review of guideline recommendations. ( 28299777 )
2017
35
Comparison of two long-term gestagen regimens in the management of recurrent vulvovaginal candidiasis: A pilot study. ( 28066940 )
2017
36
Automatic diagnosis of vulvovaginal candidiasis from Pap smear images. ( 28419509 )
2017
37
Effectiveness of Ageratina pichinchensis Extract in Patients with Vulvovaginal Candidiasis. A Randomized, Double-Blind, and Controlled Pilot Study. ( 28299831 )
2017
38
Emergence of Candida glabrata in vulvovaginal candidiasis should be attributed to selective pressure or virulence ability? ( 28730269 )
2017
39
Molecular identification and antifungal susceptibility profile of<i>Candida</i>species isolated from patients with vulvovaginitis in Tehran, Iran. ( 29387119 )
2017
40
Comparison of enzymatic activities in different Candida species isolated from women with vulvovaginitis. ( 28236530 )
2017
41
Prevalence of Candida albicans, Candida dubliniensis and Candida africana in pregnant women suffering from vulvovaginal candidiasis in Argentina. ( 28385421 )
2017
42
Evaluation of esterase and hemolysin activities of different <i>Candida</i> species isolated from vulvovaginitis cases in Lorestan Province, Iran. ( 29707672 )
2017
43
Comparison of vaginal ointment of honey and clotrimazole for treatment of vulvovaginal candidiasis: A random clinical trial. ( 28760590 )
2017
44
Identification of <i>Candida</i> species isolated from vulvovaginitis using matrix assisted laser desorption ionization-time of flight mass spectrometry. ( 29707675 )
2017
45
Is MBL serum concentration a reliable predictor for recurrent vulvovaginal candidiasis? ( 29110332 )
2017
46
Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole. ( 28696240 )
2017
47
Vulvovaginal candidiasis: Etiology, symptomatology and risk factors. ( 28314677 )
2017
48
Cyproterone acetate in the treatment of oestrogen hypersensitivity vulvovaginitis. ( 28718897 )
2017
49
Haemophilus influenzae vulvovaginitis associated with rhinitis caused by the same clone in a prepubertal girl. ( 28621044 )
2017
50
Efficacy of Histatin5 in a murine model of vulvovaginal candidiasis caused by Candida albicans. ( 28645176 )
2017

Variations for Vulvovaginitis

Expression for Vulvovaginitis

Search GEO for disease gene expression data for Vulvovaginitis.

Pathways for Vulvovaginitis

Pathways related to Vulvovaginitis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 CCL11 CCL5 CXCL8 IL10
2
Show member pathways
12.45 CCL11 CXCL8 HSPD1 IL10
3
Show member pathways
11.98 CCL11 CCL5 CXCL8
4 11.76 CXCL8 HSPD1 IL10
5
Show member pathways
11.56 CCL11 CCL5 CXCL8
6 11.49 CCL11 CXCL8 IL10
7
Show member pathways
11.47 CCL11 CCL5 CXCL8 IL10
8 11.44 CXCL8 IL10
9 11.34 CCL11 IL10
10 11.26 CXCL8 HSPD1
11 11.2 CXCL8 IL10
12 11.17 CCL11 CXCL8
13 11.14 CCL11 IL10
14 10.93 CCL11 CCL5 CXCL8
15 10.81 CCL5 CXCL8
16 10.49 CCL5 CXCL8 IL10

GO Terms for Vulvovaginitis

Cellular components related to Vulvovaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.02 CCL11 CCL5 CXCL8 HSPD1 IL10

Biological processes related to Vulvovaginitis according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.78 CCL11 CCL5 CXCL8 IL10
2 chemotaxis GO:0006935 9.7 CCL11 CCL5 CXCL8
3 regulation of signaling receptor activity GO:0010469 9.67 CCL11 CCL5 CXCL8 IL10
4 cellular response to tumor necrosis factor GO:0071356 9.63 CCL11 CCL5 CXCL8
5 inflammatory response GO:0006954 9.62 CCL11 CCL5 CXCL8 IL10
6 positive regulation of endothelial cell proliferation GO:0001938 9.58 CCL11 IL10
7 monocyte chemotaxis GO:0002548 9.58 CCL11 CCL5
8 lymphocyte chemotaxis GO:0048247 9.57 CCL11 CCL5
9 B cell proliferation GO:0042100 9.56 HSPD1 IL10
10 cellular response to fibroblast growth factor stimulus GO:0044344 9.55 CCL5 CXCL8
11 eosinophil chemotaxis GO:0048245 9.54 CCL11 CCL5
12 positive regulation of macrophage activation GO:0043032 9.51 HSPD1 IL10
13 response to molecule of bacterial origin GO:0002237 9.49 CXCL8 IL10
14 cytokine-mediated signaling pathway GO:0019221 9.46 CCL11 CCL5 CXCL8 IL10
15 negative regulation of G-protein coupled receptor protein signaling pathway GO:0045744 9.43 CCL5 CXCL8
16 cellular response to interleukin-1 GO:0071347 9.43 CCL11 CCL5 CXCL8
17 neutrophil activation GO:0042119 9.4 CCL5 CXCL8
18 chemokine-mediated signaling pathway GO:0070098 9.13 CCL11 CCL5 CXCL8
19 neutrophil chemotaxis GO:0030593 8.8 CCL11 CCL5 CXCL8

Molecular functions related to Vulvovaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.16 CCL11 CCL5
2 chemokine activity GO:0008009 9.13 CCL11 CCL5 CXCL8
3 cytokine activity GO:0005125 8.92 CCL11 CCL5 CXCL8 IL10

Sources for Vulvovaginitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....